Comparative Assessment of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin C as Early Biomarkers for Early Detection of Renal Failure in Patients with Hypertension

Gharishvandi, Fatemeh; Kazerouni, Faranak; Ghanei, Esmat; Rahimipour, Ali; Nasiri, Malihe

doi:10.6091/ibj.1380.2015

Cited by 13 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies, however, have shown the opposite results [ 105 , 106 ]. The study of Gharishvandi found that NGAL was superior to cystatin C and creatinine in detecting a kidney function decrease in the early stages of CKD and in predicting its progression [ 107 , 108 ]. It has also been found that in patients with CKD, NGAL concentrations were negatively correlated with the eGFR value, which reflected the severity of kidney damage [ 99 , 108 , 109 , 110 ].…”

Section: Ngal In Kidney Diseasesmentioning

confidence: 99%

The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL)

Romejko¹,

Markowska²,

Niemczyk³

2023

IJMS

View full text Add to dashboard Cite

Neutrophil gelatinase-associated lipocalin (NGAL) is a 25-kDa protein that is secreted mostly by immune cells such as neutrophils, macrophages, and dendritic cells. Its production is stimulated in response to inflammation. The concentrations of NGAL can be measured in plasma, urine, and biological fluids such as peritoneal effluent. NGAL is known mainly as a biomarker of acute kidney injury and is released after tubular damage and during renal regeneration processes. NGAL is also elevated in chronic kidney disease and dialysis patients. It may play a role as a predictor of the progression of renal function decreases with complications and mortality due to kidney failure. NGAL is also useful in the diagnostic processes of cardiovascular diseases. It is highly expressed in injured heart tissue and atherosclerostic plaque; its serum concentrations correlate with the severity of heart failure and coronary artery disease. NGAL increases inflammatory states and its levels rise in arterial hypertension, obesity, diabetes, and metabolic complications such as insulin resistance, and is also involved in carcinogenesis. In this review, we present the current knowledge on NGAL and its involvement in different pathologies, especially its role in renal and cardiovascular diseases.

show abstract

Section: Ngal In Kidney Diseasesmentioning

confidence: 99%

The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL)

Romejko¹,

Markowska²,

Niemczyk³

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…NGAL is a relatively small protein of the lipocalcin family that is the response of the nephron to tubular epithelial damage ( 25 ). Recent evidence indicates that NGAL levels are enhanced and stable in acute kidney injury, readily detectable in serum ( 26 , 27 ). Thus, elevated NGAL levels could predict CKD progression and serve as an early kidney damage marker ( 28 ).…”

Section: Discussionmentioning

confidence: 99%

Preventive effect and mechanism of compound Danshen dripping pills on contrast-induced nephropathy after percutaneous coronary interventional

Fu,

Wang,

Ying

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundContrast-induced nephropathy (CIN) is one of the most common complications after coronary stent implantation due to the extensive development of coronary catheterization technology. Compound Danshen dripping pills (CDDP) are clinically used as cardiovascular drugs, relieving systemic inflammatory response. Previous studies have observed that CDDP can decrease CIN incidence after coronary stent implantation with uncertain effectiveness.MethodsWe conducted a prospective, randomized, single-center, single-blind, controlled trial. We enrolled patients 18 years and older with unstable angina pectoris and NSTEMI who underwent PCI at the Tianjin Chest Hospital between November 1, 2021, and November 31, 2022, and followed for 30 days. Patients were randomized to CDDP and hydration therapy (10 capsules three times/day; N = 411) or hydration only (N = 411). The primary outcome was the contrast nephropathy incidence, defined as an elevation in serum creatinine by more than 25% or 44 μmol/L from baseline within 48–72 h of contrast exposure. Secondary outcomes included major adverse cardiovascular events post-surgery and during follow-up.ResultsAfter 48 h of operation, the two groups had statistical significance in Scr and BUN values (80.0 ± 12.59 vs. 84.43 ± 13.49, P < 0.05; 6.22 ± 1.01 vs. 6.40 ± 0.93, P < 0.05). The difference in Scr in 72 h between the two groups was statistically significant (76.42 ± 10.92 vs. 79.06 ± 11.58, P < 0.05). The CIN incidence was significantly lower in the CDDP group than in the hydration group. The CIN risk was significantly elevated in patients with LVEF <50%, contrast volume ≥160 ml, and hypertension, after 48 and 72 h of operation. The serum inflammation index levels NGAL, TNF-α, oxidative stress indexes SOD, and MDA significantly differed between the two groups. However, there was no significant difference in serum apoptosis indexes Bax, Bcl-2, and Casepase-9.ConclusionsCDDP pre-treatment could prevent contrast-induced nephropathy. Inflammatory response and oxidative stress could be significant in the CDDP mechanism.

show abstract

“…Initially, it was suggested to be used for diagnostic purposes for infection and some types of adenocarcinoma, while the dramatic increase in urine after kidney injury has made NGAL a biomarker used for kidney damage today. 12 In a study that includes analysis of serum and urine NGAL levels, information about the progression of chronic kidney injury independent of GFR was obtained. 13 , 14 …”

Section: Discussionmentioning

confidence: 99%

Neutrophil Gelatinase-Associated Lipocalin Level Can Predict Early Organ Damage in Primary Hypertensive Patients: A Pilot Study

et al. 2023

View full text Add to dashboard Cite

Background: Early detection and treatment of complicated arterial hypertension will prevent its effect on the target organs. In line with this purpose, we aimed to reveal the prediction capability of neutrophil gelatinase-associated lipocalin to complicated hypertension. Methods: In total, 46 patients with hypertension and 21 healthy volunteers were included in the study. Left ventricle morphology and geometry, as systolic and diastolic functions, were analyzed. Global longitudinal strain was measured from recorded apical 3-chamber views. An ophthalmic examination was performed to investigate the presence of retinopathy in individuals with hypertension. In addition, plasma neutrophil gelatinase-associated lipocalin values were evaluated via the method of the enzyme-linked immunosorbent assay. Results: Both neutrophil gelatinase-associated lipocalin levels and global longitudinal strain percentages were statistically significant between the groups with diastolic dysfunction and the groups without diastolic dysfunction. Complicated hypertension was detected in 42 patients. Here, it was found that the neutrophil gelatinase-associated lipocalin level of 144.3 ng/mL predicted complicated hypertension with 0.872 sensitivity and 0.65 specificity values. Conclusion: Analyzing neutrophil gelatinase-associated lipocalin levels in patients with hypertension in routine practice can easily and practically detect complicated hypertension patients earlier.

show abstract

Comparative Assessment of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin C as Early Biomarkers for Early Detection of Renal Failure in Patients with Hypertension

Cited by 13 publications

References 27 publications

The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL)

The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL)

Preventive effect and mechanism of compound Danshen dripping pills on contrast-induced nephropathy after percutaneous coronary interventional

Neutrophil Gelatinase-Associated Lipocalin Level Can Predict Early Organ Damage in Primary Hypertensive Patients: A Pilot Study

Contact Info

Product

Resources

About